# GE HealthCare Technologies Inc.  Share Price Target ‘$95.71’, now 7.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/ge-healthcare-technologies-inc.share-price-target-95.71-now-7.6-upside-potential/4121154239
- Published: 2024-05-01T14:00:18+01:00
- Author: Charlotte Edwards

**GE HealthCare Technologies Inc.** with ticker code (GEHC) have now 13 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The range
between the high target price and low target price is between $110.00 and $86.00
suggesting an average analyst share price target price of $95.71. (at the time of
writing). Given that the stocks previous close was at $88.94 this would imply there
is now a potential upside of 7.6%. The 50 day moving average now sits at $88.68 
while the 200 day moving average is $76.22. The market capitalization for the company
is 34.80B. The stock price for the company is currently is currently $76.24 USD

 The potential market cap would be $37,449,889,455 based on the market consensus.

The company has a dividend yield of 0.77%. Other points of data to note are a P/
E ratio of 25.08, revenue per share of $42.80 and a 5.65% return on assets.

GE HealthCare Technologies Inc. is a global medical technology, pharmaceutical diagnostics,
and digital solutions company. The Company develops, manufactures, and markets a
portfolio of products, services, and complementary digital solutions used in the
diagnosis, treatment, and monitoring of patients. The Company’s segments include
Imaging, Ultrasound, Patient Care Solutions and Pharmaceutical Diagnostics. The 
Imaging segment includes scanning devices, clinical applications, service capabilities
and digital solutions. The Ultrasound segment includes screening, diagnosis, treatment,
and monitoring of certain diseases. The Patient Care Solutions segment includes 
medical devices, services, consumable products, services, and digital solutions.
The Pharmaceutical Diagnostics segment is a supplier of diagnostic agents to the
global radiology and nuclear medicine industry.

Share on: